CN119256014A - 人源化抗cd45抗体 - Google Patents

人源化抗cd45抗体 Download PDF

Info

Publication number
CN119256014A
CN119256014A CN202380042580.8A CN202380042580A CN119256014A CN 119256014 A CN119256014 A CN 119256014A CN 202380042580 A CN202380042580 A CN 202380042580A CN 119256014 A CN119256014 A CN 119256014A
Authority
CN
China
Prior art keywords
seq
amino acid
variable region
chain variable
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380042580.8A
Other languages
English (en)
Chinese (zh)
Inventor
赵乐群
海伦·科塔尼德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinide Pharmaceutical Co ltd
Original Assignee
Actinide Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinide Pharmaceutical Co ltd filed Critical Actinide Pharmaceutical Co ltd
Publication of CN119256014A publication Critical patent/CN119256014A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202380042580.8A 2022-03-24 2023-03-24 人源化抗cd45抗体 Pending CN119256014A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263323257P 2022-03-24 2022-03-24
US63/323,257 2022-03-24
US202263405237P 2022-09-09 2022-09-09
US63/405,237 2022-09-09
US202263407979P 2022-09-19 2022-09-19
US63/407,979 2022-09-19
PCT/US2023/064941 WO2023183927A2 (en) 2022-03-24 2023-03-24 Humanized anti-cd45 antibodies

Publications (1)

Publication Number Publication Date
CN119256014A true CN119256014A (zh) 2025-01-03

Family

ID=88102093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380042580.8A Pending CN119256014A (zh) 2022-03-24 2023-03-24 人源化抗cd45抗体

Country Status (6)

Country Link
US (2) US11981741B2 (https=)
EP (1) EP4490197A4 (https=)
JP (1) JP2025510189A (https=)
CN (1) CN119256014A (https=)
CA (1) CA3246544A1 (https=)
WO (1) WO2023183927A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN118620078B (zh) * 2024-07-09 2024-11-19 武汉爱博泰克生物科技有限公司 抗人cd45ra蛋白的抗体、抗体偶联物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029636B2 (en) * 2008-02-05 2015-05-12 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
CN104710504B (zh) 2009-07-22 2019-09-13 锕医药股份有限公司 用于制备放射性免疫缀合物的方法
JP6047142B2 (ja) * 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
CA2861003C (en) * 2012-01-13 2023-03-28 Julius-Maximilians-Universitat Wurzburg Dual antigen-induced bipartite functional complementation
EP3297684B1 (en) 2015-05-21 2020-12-23 Actinium Pharmaceuticals, Inc. Infusion administration of conjugated monoclonal antibodies
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017155937A1 (en) 2016-03-07 2017-09-14 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
JP2020530280A (ja) * 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
WO2019084273A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES
WO2020092655A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Methods for allogeneic hematopoietic stem cell transplantation
WO2020132672A1 (en) * 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
WO2020159656A1 (en) 2019-02-01 2020-08-06 Actinium Pharmaceuticals, Inc. Molecules and their derivatives directed against cd45
JP7650819B2 (ja) 2019-04-24 2025-03-25 ブイオーアール バイオファーマ インコーポレーテッド 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用
CA3137908A1 (en) * 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
US12605472B2 (en) 2019-09-17 2026-04-21 Actinium Pharmaceuticals, Inc. Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof
WO2022040577A1 (en) 2020-08-20 2022-02-24 City Of Hope Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells

Also Published As

Publication number Publication date
EP4490197A4 (en) 2026-04-29
CA3246544A1 (en) 2023-09-28
US11981741B2 (en) 2024-05-14
US20240301081A1 (en) 2024-09-12
JP2025510189A (ja) 2025-04-14
EP4490197A2 (en) 2025-01-15
WO2023183927A3 (en) 2023-11-09
US20240010744A1 (en) 2024-01-11
WO2023183927A2 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US11981741B2 (en) Humanized anti-CD45 antibodies
JP2025143317A (ja) ポリペプチドの放射性標識
JP2975677B2 (ja) 架橋抗体およびその製造方法
CN102762230B (zh) 放射免疫偶联物和其用途
Sharifi et al. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors
AU2022213825A1 (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
Hu et al. IgG-binding nanobody capable of prolonging nanobody-based radiotracer plasma half-life and enhancing the efficacy of tumor-targeted radionuclide therapy
JP2025510189A5 (https=)
WO2024055040A2 (en) Humanized anti-cd45 antibodies
IL302759A (en) Macrocyclic compounds and methods of use thereof
JP2024519970A (ja) 三価放射性同位体生物標的放射性医薬品、調製方法及び使用
EP4429718A1 (en) Macrocyclic compounds and diagnostic uses thereof
JP2022523360A5 (https=)
Vaickus et al. Biotechnology Update: Overview of Monoclonal Antibodies in the Diagnosis and Therapy of Cancer
US20230312742A1 (en) CD38 antibodies for the treatment of human diseases
EP4138931A1 (en) B7h3 antibodies with chelators
KR20210030955A (ko) Dota-사전표적화된 방사면역요법을 위한 n-아세틸갈락토사미노 덴드론-제거제
US20250099635A1 (en) Iimmunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
US20240216557A1 (en) Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof
TW202400240A (zh) 抗ｖｅｇｆ抗體的放射性複合體及放射性醫藥
JP2026503265A (ja) Ｌ１ｃａｍを標的とする抗体およびその使用
EA048132B1 (ru) Макроциклические хелаторы и способы их применения
Hamblett Optimization of pretargeted radioimmunotherapy
Schmitz-Dräger et al. Monoclonal antibodies and renal cell carcinoma—current possibilities and future options
EA045797B1 (ru) Радиоактивное мечение полипептидов

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination